M. Voi

发表

Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study.

E. D. de Vries, E. Van Cutsem, James C Yao, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial.

G. Hortobagyi, S. Chandarlapaty, J. Baselga, 2016, JAMA oncology.

Economic value of gemcitabine compared to cisplatin and etoposide in non-small cell lung cancer.

F. A. Dorr, R. C. McDonald, C. Copley-Merriman, 1996, Lung cancer.

Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study.

F. Shepherd, M. Tonato, U. Gatzemeier, 1996, European journal of cancer.

Adjunctive everolimus for children and adolescents with treatment-refractory seizures associated with tuberous sclerosis complex: post-hoc analysis of the phase 3 EXIST-3 trial.

J. French, H. Ikeda, R. Nabbout, 2018, The Lancet. Child & adolescent health.

Everolimus dosing recommendations for tuberous sclerosis complex–associated refractory seizures

J. French, M. Kohrman, C. Brandt, 2018, Epilepsia.

Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis

K. Budde, J. Bissler, M. Fischereder, 2018, PloS one.

Everolimus in advanced, progressive, well‐differentiated, non‐functional neuroendocrine tumors: RADIANT‐4 lung subgroup analysis

E. Van Cutsem, James C Yao, Siddharth Singh, 2017, Cancer science.

Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary

S. Libutti, James C Yao, N. Fazio, 2017, Neuroendocrinology.

A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial

R. Salazar, R. Riechelmann, E. Van Cutsem, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study

J. Hainsworth, E. Baudin, M. Pavel, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancer.

A. Carrato, E. Felip, L. Paz-Ares, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Everolimus Effect on Gastrin and Glucagon in Pancreatic Neuroendocrine Tumors.

E. D. de Vries, E. Baudin, James C Yao, 2017, Pancreas.

Confirmatory activity of gemcitabine in non small cell lung cancer (NSCLC)

F. Shepherd, M. Tonato, U. Gatzemeier, 1993 .

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.

A. Hauschild, D. Schadendorf, K. Flaherty, 2019, The New England journal of medicine.

Cefaclor advanced formulation versus cefaclor in the treatment of pneumonia.

M. Voi, L. Casali, W. Dere, 1992, Clinical therapeutics.

R. Salazar, R. Riechelmann, E. Van Cutsem, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Reply to V. Amoroso et al.

James C Yao, M. Pavel, M. Voi, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Everolimus (EVE) in advanced, nonfunctional, well-differentiated neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin: second interim overall survival (OS) results from the RADIANT-4 Study.

James C Yao, N. Fazio, M. Pavel, 2016 .

Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials

C. Porta, A. Ravaud, R. Figlin, 2016, Clinical genitourinary cancer.

Phase I clinical study of the novel epothilone B analogue BMS-310705 given on a weekly schedule.

C. Sessa, S. Marsoni, L. Gianni, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies.

M. Ghielmini, R. Plummer, C. Sessa, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I and Pharmacokinetic Study of the New Taxane Analog BMS-184476 Given Weekly in Patients with Advanced Malignancies 1

M. Ghielmini, R. Plummer, C. Sessa, 2002 .

Efficacy of Dasatinib in Patients with Chronic Phase Philadelphia Chromosome-Positive CML Resistant or Intolerant to Imatinib: First Results of the CA180013 ‘START-C’ Phase II Study.

R. Larson, M. Baccarani, C. Sawyers, 2005 .

Abstract S2-07: cfDNA analysis from BOLERO-2 plasma samples identifies a high rate of ESR1 mutations: Exploratory analysis for prognostic and predictive correlation of mutations reveals different efficacy outcomes of endocrine therapy–based regimens

G. Hortobagyi, S. Chandarlapaty, J. Baselga, 2016 .

Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancer.

L. Seymour, F. Shepherd, M. Tonato, 2004, Lung cancer.

Identification of efficacy biomarkers in a large metastatic renal cell carcinoma (mRCC) cohort through next generation sequencing (NGS): Results from RECORD-3.

N. Socci, M. Berger, William Lee, 2015 .

Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

James C Yao, N. Fazio, M. Pavel, 2016, The Lancet.

Efficacy and safety of everolimus in advanced, progressive, nonfunctional neuroendocrine tumors (NET) of the gastrointestinal (GI) tract and unknown primary: A subgroup analysis of the phase III RADIANT-4 trial.

S. Libutti, James C Yao, N. Fazio, 2016 .

Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study.

E. D. de Vries, E. Van Cutsem, James C Yao, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and efficacy of everolimus in advanced nonfunctional Neuroendocrine Tumors (NET) of lung or Gastrointestinal (GI) origin: findings of the randomized, placebo-controlled, double-blind, multicenter, phase 3 RADIANT-4 study

Y. Shimada, James C Yao, N. Fazio, 2016 .

134ORADIANT-4: Efficacy and safety of everolimus in advanced, nonfunctional neuroendocrine tumors (NET) of the lung or gastrointestinal (GI) tract

Y. Shimada, James C Yao, S. Singh, 2015 .

5LBA Everolimus in advanced nonfunctional neuroendocrine tumors (NET) of lung or gastrointestinal (GI) origin: Efficacy and safety results from the placebo-controlled, double-blind, multicenter, Phase 3 RADIANT-4 study

Y. Shimada, James C Yao, N. Fazio, 2015 .

Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study

J. French, P. J. Vries, H. Ikeda, 2016, The Lancet.

An investigational new drug treatment program for patients with gemcitabine

R. Schilsky, M. Rothenberg, A. Storniolo, 1999, Cancer.

H2 antagonists and gastric ulcer: A multicenter, randomized, double-blind, controlled study comparing nizatidine with ranitidine

A. D'Angelo, M. Voi, F. Vianello, 1993 .

Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling

M. Voi, Xiong Cai, H. Qu, 2012, Clinical Cancer Research.

Everolimus for treatment-refractory seizures in TSC

J. French, H. Ikeda, R. Nabbout, 2018, Neurology. Clinical practice.

Integrative biomarker analyses indicate etiological variations in hepatocellular carcinoma.

Derek Y. Chiang, A. Zhu, J. Furuse, 2016, Journal of hepatology.

Overcoming kinase resistance in chronic myeloid leukemia.

F. Lee, M. Voi, A. Fandi, 2008, The international journal of biochemistry & cell biology.

Genomic profiling of NETs: a comprehensive analysis of the RADIANT trials.

Michael P. Morrissey, A. Garg, E. Van Cutsem, 2019, Endocrine-related cancer.

Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.

N. Socci, A. Viale, M. Berger, 2017, European urology.

Phase I First-in-Human Study of CUDC-101, a Multitargeted Inhibitor of HDACs, EGFR, and HER2 in Patients with Advanced Solid Tumors

A. Tolcher, Toshio Shimizu, P. LoRusso, 2014, Clinical Cancer Research.

Cancer Therapy : Clinical Phase I First-inHuman Study of CUDC-101 , a Multitargeted Inhibitor of HDACs , EGFR , and HER 2 in Patients with Advanced Solid Tumors

A. Tolcher, Toshio Shimizu, P. LoRusso, 2014 .

Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors

G. Demetri, V. Brunton, S. Agrawal, 2009, Clinical Cancer Research.

Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.

R. Motzer, P. Russo, T. Choueiri, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors

G. Demetri, V. Brunton, S. Agrawal, 2009, Clinical Cancer Research.

Cancer Therapy : Clinical Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors

G. Demetri, V. Brunton, S. Agrawal, 2009 .

A phase I/II study to assess the safety and efficacy of pazopanib (PAZ) and pembrolizumab (PEM) in patients (pts) with advanced renal cell carcinoma (aRCC).

M. Voss, J. Infante, S. Chowdhury, 2017 .

Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin.

C. Sessa, S. Marsoni, M. Voi, 2004, European journal of cancer.

Phase I Trial with BMS-275183, a Novel Oral Taxane with Promising Antitumor Activity

G. Giaccone, E. D. de Vries, J. Gietema, 2006, Clinical Cancer Research.

Potential Advantages of CUDC-101, a Multitargeted HDAC, EGFR, and HER2 Inhibitor, in Treating Drug Resistance and Preventing Cancer Cell Migration and Invasion

P. Savagner, M. Voi, Abdelkader Selmi, 2013, Molecular Cancer Therapeutics.

Chemical Therapeutics Potential Advantages of CUDC-101 , a Multitargeted HDAC , EGFR , and HER 2 Inhibitor , in Treating Drug Resistance and Preventing Cancer Cell Migration and Invasion

JingWang, P. Savagner, M. Voi, 2013 .

Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors.

J. Baselga, E. Felip, J. Albanell, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I Pharmacokinetic and Pharmacodynamic Study of the Farnesyl Transferase Inhibitor BMS-214662 in Combination with Cisplatin in Patients with Advanced Solid Tumors

H. Mackay, J. Verweij, R. Hoekstra, 2004, Clinical Cancer Research.

Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study

K. Budde, J. Bissler, P. D. de Vries, 2017, PloS one.

Final overall survival analysis for the RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (mRCC).

R. Motzer, K. Pittman, C. Barrios, 2015 .

PILLAR-2: A randomized, double-blind, placebo-controlled, phase III study of adjuvant everolimus (EVE) in patients (pts) with poor-risk diffuse large B-cell lymphoma (DLBCL).

F. Cavalli, M. Hino, T. Witzig, 2016 .

Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial

F. Cavalli, M. Ogura, M. Hino, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

A First-In-Man Phase 1 Study Of CUDC-907, a First-In-Class Chemically-Designed Dual Inhibitor Of PI3K and HDAC In Patients With Refractory Or Relapsed Lymphoma and Multiple Myeloma

I. Flinn, Y. Oki, A. Fattaey, 2013 .

Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma

R. Motzer, A. Hakimi, J. Hsieh, 2016, British Journal of Cancer.

Everolimus in ileum neuroendocrine tumours – Authors' reply

S. Singh, M. Voi, N. Rouyrre, 2016, The Lancet.

Differential overall survival (OS) results in RECORD-3 study based on three distinct mRCC molecular subgroups classified by BAP1 and/or PBRM1 mutations.

M. Berger, William Lee, R. Motzer, 2016 .

Everolimus for treatment-refractory seizures in TSC Extension of a randomized controlled trial

J. French, P. J. Vries, R. Nabbout, 2022 .

Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19.

K. Gelmon, J. Dancey, L. Seymour, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18.

A. Bezjak, L. Seymour, F. Shepherd, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

J. Hainsworth, E. Baudin, M. Pavel, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

R. Salazar, R. Riechelmann, E. Van Cutsem, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

383 POSTER A Phase I Study of dasatinib, a Src and multi-kinase inhibitor, in patients (pts) with GIST and other solid tumors

G. Demetri, P. LoRusso, V. Brunton, 2006 .

A phase Ib study of CUDC-101, a multitargeted inhibitor of EGFR, HER2, and HDAC, in patients with advanced head and neck, gastric, breast, liver, and non-small cell lung cancer.

J. Nemunaitis, J. Bauman, G. Dy, 2012 .

Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.

R. Motzer, P. Russo, T. Choueiri, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genomic profiling of NETs: a comprehensive analysis of the RADIANT trials.

Michael P. Morrissey, A. Garg, E. Van Cutsem, 2019, Endocrine-related cancer.